In fact, previous studies that investigated the effects of anti-CD20 antibody rituximab on T lymphocytes in RA revealed that this compound is able to deplete CD4+Th17 cells in PB and synovium as they coexpress CD20 [86–88]. Here, CD4 is linked to rheumatoid arthritis.